BioWorld

June 1, 2009

Celldex Extending Pipeline, Cash Runway in $95M CuraGen Deal

Celldex Therapeutics Inc. took another step toward expanding its pipeline, agreeing to buy CuraGen Corp. in a $94.5 million stock deal that will bring in 11 drug candidates and some added cash. (BioWorld Today) Read More

ASCO 2009 Kicks Off with Data in Hematologic Malignancies

Catalyst's Phase II Cocaine-Habit Failure Puts Squeeze on Finances

FDA Says Restrictive REMS Plan for Opioid Products Not Imminent

FDA Panel Backs Genmab's Arzerra in Refractory CLL

Other News To Note

Appointments And Advancements

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...